June 1, 2022Open Access

Phase 1, dose-escalation study of guadecitabine (SGI-110) in combination with pembrolizumab in patients with solid tumors

Key Points

Key points are not available for this paper at this time.

Abstract

Guadecitabine in combination with pembrolizumab is tolerable with biological and anticancer activity. Reversal of previous resistance to immune checkpoint inhibitors is demonstrated.

Connected Papers

Building similarity graph...

Analyzing shared references across papers

Discussion

Authors

Dionysis Papadatos-Pastos

University College London Hospitals NHS Foundation Trust

Wei Yuan

Shanghai Public Health Clinical Center

Abhijit Pal

Camden and Campbelltown Hospitals

Journals

SHILAP Revista de lepidopterología

Journal for ImmunoTherapy of Cancer

Actions

Institutions

University College London

Imperial College London

Institute of Cancer Research

References and Citations

Connected Papers

Building similarity graph...

Analyzing shared references across papers

Phase 1, dose-escalation study of guadecitabine (SGI-110) in combination with pembrolizumab in patients with solid tumors

Key Points

Abstract

Citation Network

Connected Papers

Discussion

Authors

Journals

Actions

Institutions

References and Citations

Citation Network

Connected Papers

Discussion

Cite this study

Also consider

Also consider